Encouraging Interim Trial Results for Hep C Non-Responders
Anadys achieves positive interim results in ongoing phase 2b hepatitis C study
October 13, 2011
by Olivia D’Orazio
Anadys Pharmaceuticals (NASDAQ:ANDS) announced Thursday positive interim results in its ongoing phase 2b study of setrobuvir, in combination with pegylated interferon and ribavirin (P/R), in patients with the hepatitis C virus.
The study dosed 283 patients suffering from hepatitis C, who were either treatment naive, or experienced either a relapse or no response to previous P/R treatments.
Continue reading this entire article:
Hepatitis C Triple Therapy Response Predicted in Four Weeks
Biotica Seeking Patent for New Class of Hepatitis C Drug